Viral gastroenteritis, frequently referred to as the “stomach flu,” is an intense and exhausting illness that strikes the digestive system. It often arrives suddenly, bringing waves of nausea, vomiting, and diarrhea that can make even leaving the bathroom feel impossible. The physical toll is significant, leaving patients feeling weak, drained, and dehydrated. While the condition is usually temporary and resolves on its own, the symptoms can be severe enough to disrupt daily life completely.

Treatment is essential not to cure the virus itself, but to manage the aggressive symptoms and prevent complications. The most dangerous aspect of viral gastroenteritis is dehydration, the rapid loss of fluids and electrolytes. Because the infection is viral, antibiotics are ineffective and are not used. Instead, treatment plans focus on supportive care and symptom control. Management strategies depend heavily on the severity of fluid loss and the patient’s ability to keep liquids down (National Institute of Diabetes and Digestive and Kidney Diseases, 2017).

Overview of treatment options for Viral Gastroenteritis

The primary goal of treating viral gastroenteritis is to prevent dehydration and relieve abdominal distress. Since there is no medication to kill the viruses (such as norovirus or rotavirus) responsible for the infection, the immune system must clear the virus naturally.

Medical intervention centers on controlling vomiting and diarrhea to allow the patient to rest and rehydrate. In mild cases, oral rehydration solutions and rest are sufficient. However, when vomiting is frequent or diarrhea is profuse, medications are used to stabilize the digestive tract. These are typically used for acute symptom relief rather than long-term management. It is important to distinguish viral gastroenteritis from bacterial infections, as the use of certain medications may differ.

Medications used for Viral Gastroenteritis

The first priority in medication management is often stopping the vomiting so that oral rehydration can occur. Antiemetics (anti-vomiting medications) are the first-line drug class for this purpose. Ondansetron is widely prescribed and is highly effective at curbing severe nausea. Clinical experience suggests that a single dose of an antiemetic can often prevent the need for intravenous (IV) fluids in emergency settings. Older medications like promethazine may also be used, though they are more sedating.

To manage intestinal symptoms, antidiarrheal agents are commonly used for adults. Loperamide is the standard over-the-counter choice to slow down bowel movements. Another option is bismuth subsalicylate, which helps coat the stomach lining and reduce inflammation.

It is important to note that antidiarrheals are generally avoided in children or in cases where there is high fever or bloody stool, as slowing the gut can sometimes trap bacteria. Patients typically experience relief from nausea within 30 to 60 minutes of taking an antiemetic, allowing them to begin sipping fluids again (Mayo Clinic, 2022).

How these medications work

Antiemetics like ondansetron work by blocking specific chemical signals in the body. They target serotonin receptors in both the gut and the brain’s “vomiting center.” By interrupting the message that tells the brain to trigger the vomiting reflex, the stomach settles, and the urge to vomit subsides.

Antidiarrheals like loperamide work by acting on the muscle receptors in the intestines. They slow down the rhythmic contractions that push food through the digestive tract. This delay gives the large intestine more time to absorb water from the stool, making it firmer and reducing the frequency of bathroom trips. Bismuth subsalicylate has a mild antimicrobial action and prevents fluids from being secreted into the bowel (MedlinePlus, 2021).

Side effects and safety considerations

While these medications provide much-needed relief, they have side effects. Ondansetron can cause headaches, constipation, or fatigue; Promethazine causes significant drowsiness. Antidiarrheals may cause constipation if overused.

Bismuth subsalicylate can temporarily turn the tongue and stool black, a harmless but alarming side effect. Prioritize safety, especially for children and older adults. Children/teens must use aspirin-free products to avoid Reye’s syndrome. Patients should seek immediate medical care for signs of severe dehydration (dry mouth, no urine for 8 hours, confusion), bloody diarrhea, or severe lower right abdominal pain.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov
  2. Mayo Clinic. https://www.mayoclinic.org
  3. MedlinePlus. https://medlineplus.gov
  4. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov

Medications for Viral Gastroenteritis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Viral Gastroenteritis.

Found 45 Approved Drugs for Viral Gastroenteritis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa
Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.'s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 )

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs
Sulfasalazine delayed release tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and d) in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. Sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent.

Entyvio

Generic Name
Vedolizumab

Entyvio

Generic Name
Vedolizumab
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Adalimumab

Brand Names
Adalimumab-aacf, Humira

Adalimumab

Brand Names
Adalimumab-aacf, Humira
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Showing 1-5 of 45
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances